Organization
Addpharma
10 clinical trials
Clinical trial
A Parallel, Open-Label, Single-Dose Administration, Phase 1 Clinical Study to Assess the Safety and Pharmacokinetics of AD-104-A in Healthy Adult Volunteers and Patients With Renal ImpairmentStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Randomized, Open-label, 2x2 Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics After Oral Administration of AD-212-A or AD-2121 in Healthy Adult VolunteersStatus: Recruiting, Estimated PCD: 2024-06-15
Clinical trial
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential HypertensionStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients With Essential HypertensionStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential HypertensionStatus: Completed, Estimated PCD: 2023-11-27
Clinical trial
A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients With Mixed DyslipidemiaStatus: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential HypertensionStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AD-208 in Male Patients With Androgenetic AlopeciaStatus: Completed, Estimated PCD: 2023-01-09
Clinical trial
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients With Essential HypertensionStatus: Not yet recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 in Patients With Primary Hypercholesterolemia and Essential HypertensionStatus: Completed, Estimated PCD: 2021-11-22